Trial Profile
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Vadastuximab talirine (Primary) ; Azacitidine; Azacitidine; Decitabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Seagen
- 25 Jul 2018 Results (n=53) assessing safety, tolerability and acitivity of vadastuximab talirine with HMA published in the Blood
- 03 Jan 2018 Status changed from active, no longer recruiting to completed.
- 25 Jun 2017 Results (n=53) of 33A+HMA cohort, presented at the 22nd Congress of the European Haematology Association